
    
      The goal of this study is to determine if 8 weeks of preemptive and sustained administration
      of pan-genotypic DAA therapy after kidney transplant prevents the transmission of hepatitis C
      virus (HCV) infection from an HCV-positive donor kidney to an HCV-naive recipient.
    
  